The WeDecide study is looking at two treatments for kids with sickle cell disease (SCD): matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT). MRD HCT is a procedure where healthy blood-making cells from a family member are given to the patient. NT-DMT includes medicines that help manage the disease without a transplant. The study focuses on the quality of life, brain function, and health risks over three years. It involves 480 children aged 3 to 20.9 years. By comparing these treatments, the study aims to help families and doctors choose the best care. They will track health, hospital visits, and any complications.
- The study lasts for three years with multiple health check-ups.
- Participants are divided into two groups: 160 for MRD HCT and 320 for NT-DMT.
- Information from this study will help guide future treatment decisions for SCD.